mTOR activation in well differentiated pancreatic neuroendocrine tumors: A retrospective study on 34 cases

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 2140-2143

  Zhou, Chen Fei ^a   Ji, Jun ^a   Yuan, Fei ^a   Shi, Min ^a   Zhang, Jun ^a   Liu, Bing Ya ^a   Zhu, Zheng Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Classification; mTOR; Pancreatic neuroendocrine tumor

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; DISEASE CLASSIFICATION; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL;

CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES;

EID: 84863259213     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11212     Document Type: Article

References (22)

1. Ong SL, Garcea G, Pollard CA, et al.: A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology 2009; 9:583-600.
2. Khan A: Surgical pathology of endocrine and neuroendocrine tumor. Humana Press: 2009-07-30, ISBN: 1603273956.
3. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM: Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727-33.
4. Yao JC, Hassan M, Phan A, et al.: One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063-72.
5. Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2:45.
6. Missiaglia E, Dalai I, Barbi S, et al.: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245-55.
7. Agarwala SS, Case S: Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010; 15:236-45.
8. Yao JC, Shah MH, Ito T, et al.: RADOOl in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-23.
9. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S: The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading and staging systems. Pancreas 2010; 39:707-12
10. Hill JS, McPhee JT, McDade TP, et al.: Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009; 115:741-51.
11. Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-71
12. Mitry E, Baudin E, Ducreux M, et al.: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351-5.
13. Pavel M, Hainsworth JD, Baudin E, et al.: A randomized, double-blind, placebo-controlled, multicenter phase iii trial of everolimus + octreotide lar vs placebo + octreotide lar in patients with advanced neuroendocrine tumors (net) (radiant-2). Ann Oncol 2010; 21(Suppl 8):viii1-viii12.
14. Marinov M, Ziogas A, Pardo OE, et al.: AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RADOOl. Clin Cancer Res 2009; 15:1277-87.
15. Shida T, Kishimoto T, Furuya M, et al.: Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65:889-93.
16. Zitzmann K, De Toni EN, Brand S, et al.: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85:54-60. (Pubitemid 46550026)
17. Zhou L, Huang Y, Li J, Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27:255-61
18. Hirashima K, Baba Y, Watanabe M, et al.: Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2010; 17:2486-93
19. Herberger B, Puhalla H, Lehnert M, et al.: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007; 13:4795-9. (Pubitemid 47294786)
20. Yu G, Wang J, Chen Y, et al.: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009; 15:1821-9.
21. Chalhoub N, Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4:127-50.
22. Neshat MS, Mellinghoff IK, Tran C, et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98:10314-9. (Pubitemid 32803017)